Page last updated: 2024-12-11

vinzolidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

vinzolidine: orally active, semisynthetic vinca alkaloid; RN refers to (3R-(3R*,5S*,7R*,9S*)-isomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
VincagenusA plant genus of the family Apocynaceae.[MeSH]ApocynaceaeThe dogbane family of the order Gentianales. Members of the family have milky, often poisonous juice, smooth-margined leaves, and flowers in clusters.[MeSH]

Cross-References

ID SourceID
PubMed CID146159486
MeSH IDM0125212

Synonyms (3)

Synonym
vinzolidine
ly 104208
67699-40-5

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"Vinzolidine (VZL), a novel, semi-synthetic vinca alkaloid showing evidence of oncolytic activity in phase I/II clinical trials, was studied in six patients for its pharmacokinetic and metabolic behavior."( Clinical pharmacokinetics of intravenously injected tritiated vinzolidine.
Bergstrom, RF; Budman, DR; Freeman, J; Kreis, W; Nelson, RL, 1990
)
0.28
" The measured pharmacokinetic parameters conformed best to a 2-compartment model with a mean terminal half-life of 23 hours."( A phase I and pharmacokinetic study of intravenous vinzolidine.
Alberts, DS; Holdsworth, MT; McCloskey, TM; Plezia, PM; Robertone, AB; Salmon, SE; Satterlee, WG; Taylor, CW, 1990
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (70.00)18.7374
1990's3 (30.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (18.18%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (81.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]